Connor, Clark & Lunn Investment Management Ltd. Pacira Bio Sciences, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 44,137 shares of PCRX stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,137
Previous 80,533
45.19%
Holding current value
$1.11 Million
Previous $1.21 Million
31.44%
% of portfolio
0.0%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$201 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$132 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$82.1 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$56.8 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$50.1 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.15B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...